Investors Driving Digpatho’s Future
Discover how our investors are transforming the field of pathology with advanced artificial intelligence technology.
Meet Our Valued Investors
Our investors share a common vision: to revolutionize pathology through artificial intelligence. Each brings a unique mission that aligns perfectly with Digpatho’s goals. From improving diagnostic accuracy to accelerating analysis times, our partners are critical to our continued success and growth in the digital health sector.
Join Our Mission
Discover how you can contribute to the advancement of pathology with artificial intelligence. Your support can make a difference in the future of healthcare.
Testimonials
Our Investors
“Focused on innovation and digital transformation efforts, with a deep sense of strategic interactions with stakeholders and customers while implementing solutions with Artificial Intelligence and Machine Learning seeking improvements in customer service and cost reduction.“
Octavio Carranza
“He has held general management positions in national and international companies, such as Grupo Electrico Endesa of Spain (DG of the Mexico office), among other companies, and has been a member of the boards of Mexican and international companies..“
Gustavo López Padilla
FAQ
What is the main goal of your project?
Our mission is to revolutionize cancer diagnostics through AI-powered solutions, enabling early detection, increased accuracy, and better patient outcomes, starting with breast cancer and expanding to other types such as prostate and HER2+ cancers.
How do you plan to generate revenue?
We offer our AI diagnostic tools as a B2B SaaS platform for pathology labs, hospitals, and research institutions, with subscription-based pricing, scalable cloud deployment, and API integrations.
What differentiates your technology from others in the market?
Our technology focuses on interpretability, integration with existing workflows, and high-performance models trained on diverse datasets, reducing interobserver variability and improving diagnostic precision.
What milestones have you achieved so far?
We have successfully developed and tested our AI model for breast cancer detection, built a scalable platform, partnered with pilot institutions, and are expanding features for HER2, hormone receptors, and prostate cancer.
How can investors get involved?
We are currently open to strategic partnerships and early-stage investment to accelerate product development, expand our team, and grow our reach in the medical diagnostics space. Interested investors can contact us directly through our Investor Relations section.